A study on SCLC, characterized by an aggressive course and a poor prognosis, showed that reducing UHRF1 levels increased the chemosensitivity of SCLC cells to cisplatin, a cornerstone in the combination chemotherapy regimen for this type of lung cancer [62]. This evidence concerns the gene UHRF1 and lung cancer.